Ixico Regulatory News (IXI)

IXICO plc

("IXICO", the "Company" or the "Group")

Global clinical trial contract wins in Alzheimer's Disease

and Friedreich's Ataxia

12 August 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications. The combined value of the new contracts is circa £1.3 million.

Under the first contract IXICO will provide trial management and imaging analysis for a Phase 1 Alzheimer's Disease (AD) clinical trial by a major pharmaceutical company. The contract scope covers a collaboration for approximately three and a half years. 

The second contract with a US-based biotech sees IXICO facilitating high quality imaging data collection for a Phase 1b trial to aid surgical planning in Friedrich's Ataxia (FA), a progressive inherited neurodegenerative disorder that effects the nervous system and heart. The contract scope covers a collaboration for six years. 

This positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

Bram Goorden, CEO of IXICO, commented: "The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space. The two deals hit different key elements of our strategy, respectively supporting Alzheimer's as a core indication, and; maintaining our leadership position in the rare CNS disease space."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Ends

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.